Slideshow

Rheumatoid Arthritis: 3 New Things

Author(s):

What’s new: biologic tapering, high-dose influenza vaccine, real-time patient input.

References1. Dierckx S, Lauwerys BR, Sokolova T, et al. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost effective in daily clinical practice: DATA from the Brussels UCL RA Cohort. [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed November 2, 2018.2. Colmegna I, Useche M, Rodriguez K, et al. Efficacy of high-dose versus standard-dose influenza vaccine in seropositive rheumatoid arthritis patients. [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed November 2, 2018.3. Forman M, Leatherwood C, Xu C, et al. Implementation of a treat-to-target quality improvement program for rheumatoid arthritis management using real-time patient reported outcome measures [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed November 2, 2018.

Related Videos
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
© 2024 MJH Life Sciences

All rights reserved.